Terns Pharmaceuticals (TERN) Stock Statistics & Valuation Metrics

Terns Pharmaceuticals has a market cap or net worth of $6.07B. The enterprise value is $4.22B.

Terns Pharmaceuticals has 115,413,390 shares outstanding. The number of shares has decreased by -2.65% in one year.

Terns Pharmaceuticals’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -10.91%.

The current PE Ratio of Terns Pharmaceuticals is ―. Terns Pharmaceuticals’s PEG ratio is 4.87.

In the last 12 months, Terns Pharmaceuticals had revenue of 0.00 and earned -96.21M in profits. Earnings per share was -1.03.

In the last 12 months, operating cash flow was -82.18M and capital expenditures 0.00, giving a free cash flow of -82.18M billion.

Terns Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Terns Pharmaceuticals upcoming earnings date is May 18, 2026, After Close (Confirmed).

Terns Pharmaceuticals as a current ratio of 62.41, with Debt / Equity ratio of 0.09%

In the past 12 months, Terns Pharmaceuticals has paid 581.00K in taxes.

Terns Pharmaceuticals EV to EBITDA ratio is -29.42, with an EV/FCF ratio of -39.43.

Terns Pharmaceuticals has $1.02B in cash and marketable securities with $919.00K in debt, giving a net cash position of $1.02B billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Terns Pharmaceuticals is $53.00, which is 11.43% higher than the current price. The consensus rating is Hold